Skip to main content
NOVAVAX INC logo

NOVAVAX INC — Investor Relations & Filings

Ticker · NVAX ISIN · US6700024010 LEI · 529900J4GJHPEPQ23205 US Manufacturing
Open in API
Filings indexed 1,095 across all filing types
Latest filing 2014-06-09 Capital/Financing Update
Country US United States of America
Listing US NVAX

About NOVAVAX INC

https://www.novavax.com/?locale=US

Novavax Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company utilizes a proprietary, protein-based vaccine technology platform, which includes its novel Matrix-M™ adjuvant, to create its vaccine candidates. Its primary commercial product is a protein-based COVID-19 vaccine, Nuvaxovid™. Novavax's research and development pipeline is focused on addressing significant health needs, including influenza and a combination COVID-19-influenza vaccine. The company's strategy emphasizes advancing its pipeline assets and establishing strategic partnerships to maximize the global health impact of its technology.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content specifically details the entry into a material definitive agreement related to an underwriting agreement for a public offering of common stock. It includes information about the offering size, price, underwriters, and related press releases. There are no financial statements or detailed financial performance data included, nor is this an annual or quarterly report. The primary focus is on the financing activity (public offering of shares). Therefore, this document fits best under the category of Capital/Financing Update (CAP).
2014-06-09 English
FORM 424B2
Capital/Financing Update Classification · 100% confidence The document is a Form 424B2, which is a prospectus supplement related to a securities offering. It details the registration fee calculation, offering terms, underwriting discounts, and use of proceeds for a common stock offering by Novavax, Inc. The content focuses on the capital raising activity, including the number of shares offered, pricing, and underwriting details. This type of filing is specifically related to capital/financing updates rather than financial performance reports, management changes, or other categories. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement but a full prospectus supplement, supporting high confidence in this classification.
2014-06-09 English
FORM 424B5
Capital/Financing Update Classification · 100% confidence The document is a Form 424B5 preliminary prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act. It describes an offering of common stock by Novavax, Inc., including details about the offering size, underwriting, risk factors, use of proceeds, and company background. This type of document is a capital raising disclosure related to a securities offering, not a financial report, earnings release, or management discussion. It is not an announcement of a report publication but the actual offering document. Therefore, it fits the category of Capital/Financing Update (CAP).
2014-06-04 English
AUTO-GENERATED PAPER DOCUMENT
Annual Report
2014-06-03 English
QUARTERLY REPORT
Interim / Quarterly Report Q1 2014
2014-05-08 English
CURRENT REPORT
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 7, 2014, reporting the company's financial results for the quarter ended March 31, 2014. It includes a press release as an exhibit announcing the quarterly financial results. The document itself is a regulatory filing to announce the earnings results, but it does not contain the full financial statements or detailed analysis typical of an Interim/Quarterly Report (IR). The length is 3435 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such documents announcing earnings results via press release in an 8-K are classified as Earnings Release (ER).
2014-05-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.